Moderna, RSV
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's respiratory syncytial virus (RSV) vaccine be considered equal to rival shots launched last year.
Most Expectant Moms Say They're Likely to Get Maternal RSV Vaccine
Whether or not future parents already had one or more children also influenced their perceptions of the RSV vaccine. Of those with one or more children at home, 57% reported they were very likely to receive the RSV vaccine during pregnancy, compared with 50% of those with no children at home ( P =0.01).
Moderna gears up for potential RSV vaccine launch this fall after better-than-expected Q1
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024,
Moderna Results Beat Estimates as Company Prepares for RSV Shot Launch
Moderna reported first-quarter financial results Thursday that soundly beat Wall Street expectations, but the focus for investors remains on the anticipated launch of the company’s second product later this year.
Moderna’s Hold Rating Maintained Amidst Positive Sales Outlook and Awaited RSV Vaccine Launch
Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating yesterday. Joseph Stringer has given
Medical Xpress on MSN12d
Future parents more likely to get RSV vaccine when pregnant if aware RSV can be a serious illness in infants: Study
A nationwide survey of people who were pregnant or trying to become pregnant has found that overall, 54% expressed interest ...
FiercePharma5d
GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms
Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK ...
World's First RSV Vaccine For Older Adults Now Registered For Use In NZ
Arexvy is the world’s first respiratory syncytial virus (RSV) vaccine for older adults and has been registered for use in Australia, the UK, the European Union, the US, Canada and Japan. Research ...
Too Old to Operate3d
Cardiac Events in Patients With RSV Increase Virus’ Severity
Nearly a quarter of patients with RSV experience an acute cardiac event, including life-threatening conditions such as cardiogenic shock and acute myocarditis.
Daily3d
Nirsevimab use may reduce infant hospitalizations due to RSV by 82 percent: Lancet
Nirsevimab use may reduce infant hospitalizations due to respiratory syncytial virus (RSV) by 82 percent, shows real world ...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsNew real-world evidence shows Beyfortus ...
Magazine: Anticipation rises for RSV rollout as positive data emerges
Following the RSV therapy and vaccine rollout, understanding molecular glues, using pharmacovigilance for active drug ...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
The PFS ready-to-use formulation will save pharmacists and clinicians time, potentially alleviating wait times and reducing ...